SBIR/STTR Research Award
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease
Award amount
$1,500,000Program and phase
SBIR · Phase IIAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DeNovoTherapies LLC
- Proposal award date
- 2018-08-03
- Contract end date
- 2020-07-31
- UEI
- U2LMFGLFDBU5
- Solicitation number
- PA15-269
- Topic code
- NHLBI
Research abstract
TBD
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
2 SBIR/STTR records share this UEI (2017–2018). Reported award amounts total $1,725,000. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services